PL2078022T3 - Spirobenzoazepiny stosowane jako antagoniści wazopresyny - Google Patents
Spirobenzoazepiny stosowane jako antagoniści wazopresynyInfo
- Publication number
- PL2078022T3 PL2078022T3 PL07842799T PL07842799T PL2078022T3 PL 2078022 T3 PL2078022 T3 PL 2078022T3 PL 07842799 T PL07842799 T PL 07842799T PL 07842799 T PL07842799 T PL 07842799T PL 2078022 T3 PL2078022 T3 PL 2078022T3
- Authority
- PL
- Poland
- Prior art keywords
- renal
- hyponatremia
- hypertension
- insufficiency
- formula
- Prior art date
Links
- -1 Spiro benzazepines Chemical class 0.000 title 1
- 229940116211 Vasopressin antagonist Drugs 0.000 title 1
- 239000003038 vasopressin antagonist Substances 0.000 title 1
- 206010019280 Heart failures Diseases 0.000 abstract 4
- 206010007559 Cardiac failure congestive Diseases 0.000 abstract 2
- 206010020772 Hypertension Diseases 0.000 abstract 2
- 206010021036 Hyponatraemia Diseases 0.000 abstract 2
- 208000001647 Renal Insufficiency Diseases 0.000 abstract 2
- 201000006370 kidney failure Diseases 0.000 abstract 2
- 206010003225 Arteriospasm coronary Diseases 0.000 abstract 1
- 201000006474 Brain Ischemia Diseases 0.000 abstract 1
- 206010048962 Brain oedema Diseases 0.000 abstract 1
- 206010008120 Cerebral ischaemia Diseases 0.000 abstract 1
- 206010008132 Cerebral thrombosis Diseases 0.000 abstract 1
- 208000003890 Coronary Vasospasm Diseases 0.000 abstract 1
- 208000007342 Diabetic Nephropathies Diseases 0.000 abstract 1
- 206010016807 Fluid retention Diseases 0.000 abstract 1
- 201000001429 Intracranial Thrombosis Diseases 0.000 abstract 1
- 208000006011 Stroke Diseases 0.000 abstract 1
- 102000004136 Vasopressin Receptors Human genes 0.000 abstract 1
- 108090000643 Vasopressin Receptors Proteins 0.000 abstract 1
- 206010047163 Vasospasm Diseases 0.000 abstract 1
- 208000006752 brain edema Diseases 0.000 abstract 1
- 206010008118 cerebral infarction Diseases 0.000 abstract 1
- 208000019425 cirrhosis of liver Diseases 0.000 abstract 1
- 150000001875 compounds Chemical class 0.000 abstract 1
- 201000011634 coronary artery vasospasm Diseases 0.000 abstract 1
- 208000033679 diabetic kidney disease Diseases 0.000 abstract 1
- 230000000694 effects Effects 0.000 abstract 1
- 208000031225 myocardial ischemia Diseases 0.000 abstract 1
- 239000008194 pharmaceutical composition Substances 0.000 abstract 1
- 230000002792 vascular Effects 0.000 abstract 1
- 239000002536 vasopressin receptor antagonist Substances 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
- C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
- C07D487/10—Spiro-condensed systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/12—Drugs for disorders of the urinary system of the kidneys
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/20—Hypnotics; Sedatives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/22—Anxiolytics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/16—Otologicals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/12—Drugs for disorders of the metabolism for electrolyte homeostasis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P5/00—Drugs for disorders of the endocrine system
- A61P5/24—Drugs for disorders of the endocrine system of the sex hormones
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
- A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
- A61P7/10—Antioedematous agents; Diuretics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/12—Antihypertensives
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Neurology (AREA)
- Biomedical Technology (AREA)
- Neurosurgery (AREA)
- Diabetes (AREA)
- Cardiology (AREA)
- Heart & Thoracic Surgery (AREA)
- Hematology (AREA)
- Endocrinology (AREA)
- Urology & Nephrology (AREA)
- Vascular Medicine (AREA)
- Anesthesiology (AREA)
- Obesity (AREA)
- Hospice & Palliative Care (AREA)
- Psychiatry (AREA)
- Reproductive Health (AREA)
- Gastroenterology & Hepatology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
- Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
- Heterocyclic Carbon Compounds Containing A Hetero Ring Having Nitrogen And Oxygen As The Only Ring Hetero Atoms (AREA)
- Heterocyclic Carbon Compounds Containing A Hetero Ring Having Oxygen Or Sulfur (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US82665406P | 2006-09-22 | 2006-09-22 | |
| EP07842799A EP2078022B1 (en) | 2006-09-22 | 2007-09-19 | Spiro benzazepines used as vasopressin antagonists |
| PCT/US2007/078917 WO2008036755A1 (en) | 2006-09-22 | 2007-09-19 | Spiro benzazepines used as vasopressin antagonists |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| PL2078022T3 true PL2078022T3 (pl) | 2012-04-30 |
Family
ID=39030853
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| PL07842799T PL2078022T3 (pl) | 2006-09-22 | 2007-09-19 | Spirobenzoazepiny stosowane jako antagoniści wazopresyny |
Country Status (14)
| Country | Link |
|---|---|
| US (1) | US7825110B2 (2) |
| EP (1) | EP2078022B1 (2) |
| JP (1) | JP2010504351A (2) |
| CN (1) | CN101541806A (2) |
| AT (1) | ATE532786T1 (2) |
| AU (1) | AU2007299818B2 (2) |
| CA (1) | CA2665849A1 (2) |
| CY (1) | CY1112270T1 (2) |
| DK (1) | DK2078022T3 (2) |
| ES (1) | ES2374582T3 (2) |
| PL (1) | PL2078022T3 (2) |
| PT (1) | PT2078022E (2) |
| SI (1) | SI2078022T1 (2) |
| WO (1) | WO2008036755A1 (2) |
Families Citing this family (12)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP2781521A4 (en) | 2011-10-19 | 2015-03-04 | Kowa Co | NEW SPIROINDOLIN COMPOUND AND MEDICAL AGENT THEREFOR |
| HUE040133T2 (hu) | 2014-07-15 | 2019-02-28 | Gruenenthal Gmbh | Szubsztituált azaspiro(4.5)dekán származékok |
| TW201607923A (zh) | 2014-07-15 | 2016-03-01 | 歌林達有限公司 | 被取代之氮螺環（４．５）癸烷衍生物 |
| CA2991020A1 (en) | 2015-07-07 | 2017-01-12 | Japan Tobacco Inc. | Method for producing 7h-pyrrolo[2, 3-d]pyrimidine derivative and intermediate thereof |
| BR112019012688A2 (pt) * | 2016-12-21 | 2019-11-19 | Japan Tobacco Inc | método para produção de derivado de 7h-pirrol[2,3-d]pirimidina e intermediário sintético do mesmo |
| MX2020002762A (es) | 2017-09-15 | 2020-09-17 | Azevan Pharmaceuticals Inc | Composiciones y métodos para tratar una lesión cerebral. |
| WO2019141575A1 (de) | 2018-01-16 | 2019-07-25 | Bayer Aktiengesellschaft | Unterstützung bei der behandlung von herzinsuffizienz |
| KR20230050369A (ko) * | 2020-08-07 | 2023-04-14 | 카스마 테라퓨틱스, 인코포레이티드 | Trpml 조절제 |
| WO2022111581A1 (zh) * | 2020-11-26 | 2022-06-02 | 上海济煜医药科技有限公司 | 新型苯并氮杂卓螺环衍生物 |
| CN112939864B (zh) * | 2021-01-29 | 2022-05-06 | 中国医科大学 | 螺[苯并[c]氮杂-1,1’-环己基]-3-酮类化合物 |
| EP4491699A1 (de) | 2023-07-13 | 2025-01-15 | Klueber Lubrication München GmbH & Co. KG | Phthalimidverbindungen als basisöl für schmierstoffzusammensetzungen |
| WO2026002248A1 (zh) * | 2024-06-28 | 2026-01-02 | 上海济煜医药科技股份有限公司 | 作为v2受体拮抗剂的苯并氮杂卓并环衍生物 |
Family Cites Families (22)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4617302A (en) | 1984-10-15 | 1986-10-14 | Eli Lilly And Company | Inotropic agents |
| JP2905909B2 (ja) * | 1991-04-19 | 1999-06-14 | 大塚製薬株式会社 | バソプレシン拮抗剤 |
| US5985869A (en) | 1989-10-20 | 1999-11-16 | Otsuka Pharmaceutical Company, Limited | Benzoheterocyclic compounds |
| DK0450097T3 (da) | 1989-10-20 | 1996-05-20 | Otsuka Pharma Co Ltd | Benzoheterocykliske forbindelser |
| US5258510A (en) | 1989-10-20 | 1993-11-02 | Otsuka Pharma Co Ltd | Benzoheterocyclic compounds |
| US5686624A (en) | 1992-01-30 | 1997-11-11 | Sanofi | 1-benzenesulfonyl-1,3-dihydro-indol-2-one derivatives, their preparation and pharmaceutical compositions in which they are present |
| US5663431A (en) | 1992-01-30 | 1997-09-02 | Sanofi | 1-benzenesulfonyl-1,3-dihydro-indol-2-one derivatives, their preparation and pharmaceutical compositions in which they are present |
| FR2708605A1 (fr) | 1993-07-30 | 1995-02-10 | Sanofi Sa | Dérivés du N-sulfonylindol-2-one, leur préparation, les compositions pharmaceutiques en contenant. |
| US5849780A (en) | 1992-01-30 | 1998-12-15 | Sanofi | 1-benzenesulfonyl-1-1,3-dihydroindol-2-one derivatives, their preparation and pharmaceutical compositions in which they are present |
| FR2686878B1 (fr) * | 1992-01-30 | 1995-06-30 | Sanofi Elf | Derives du n-sulfonyl oxo-2 indole, leur preparation, les compositions pharmaceutiques en contenant. |
| WO1994007496A1 (en) | 1992-10-07 | 1994-04-14 | Merck & Co., Inc. | Tocolytic oxytocin receptor antagonists |
| US5512563A (en) | 1993-07-29 | 1996-04-30 | American Cyanamid Company | Tricyclic benzazepine vasopressin antagonists |
| FR2708606B1 (fr) * | 1993-07-30 | 1995-10-27 | Sanofi Sa | Dérivés du N-phénylalkylindol-2-one, leur préparation, les compositions pharmaceutiques en contenant. |
| US5464788A (en) | 1994-03-24 | 1995-11-07 | Merck & Co., Inc. | Tocolytic oxytocin receptor antagonists |
| US5753648A (en) | 1995-01-17 | 1998-05-19 | American Cyanamid Company | Tricyclic benzazepine vasopressin antagonists |
| AUPP150098A0 (en) | 1998-01-27 | 1998-02-19 | Fujisawa Pharmaceutical Co., Ltd. | Benzamide derivatives |
| US7001898B2 (en) | 2000-07-05 | 2006-02-21 | Ortho-Mcneil Pharmaceutical, Inc. | Nonpeptide substituted spirobenzoazepines as vasopressin antagonists |
| CA2432825A1 (en) * | 2000-12-15 | 2002-06-20 | Emory University | Nonpeptide agonists and antagonists of vasopressin receptors |
| US7011898B2 (en) * | 2003-03-21 | 2006-03-14 | Air Products And Chemicals, Inc. | Method of joining ITM materials using a partially or fully-transient liquid phase |
| JP2007516177A (ja) * | 2003-06-17 | 2007-06-21 | ジヤンセン・フアーマシユーチカ・ナームローゼ・フエンノートシヤツプ | 非ペプチド置換スピロベンゾアゼピン誘導体の製造方法 |
| DE602004023501D1 (de) * | 2003-06-17 | 2009-11-19 | Janssen Pharmaceutica Nv | Substituierte spirobenzazepine |
| CA2637838A1 (en) * | 2006-01-20 | 2007-07-26 | Janssen Pharmaceutica N.V. | Novel solid forms of (4r)-1-¬4-(2-chloro-5-fluorobenzoyl)amino-3-methoxybenzoyl|-1,2,3,5-tetrahydro-spiro¬4h-1-benzazepine-4,1'-¬2|cyclopentene|-3'-carboxylic acid |
-
2007
- 2007-09-19 PT PT07842799T patent/PT2078022E/pt unknown
- 2007-09-19 US US11/857,891 patent/US7825110B2/en not_active Expired - Fee Related
- 2007-09-19 DK DK07842799.4T patent/DK2078022T3/da active
- 2007-09-19 WO PCT/US2007/078917 patent/WO2008036755A1/en not_active Ceased
- 2007-09-19 PL PL07842799T patent/PL2078022T3/pl unknown
- 2007-09-19 SI SI200730800T patent/SI2078022T1/sl unknown
- 2007-09-19 AU AU2007299818A patent/AU2007299818B2/en not_active Expired - Fee Related
- 2007-09-19 CA CA002665849A patent/CA2665849A1/en not_active Abandoned
- 2007-09-19 CN CNA2007800432003A patent/CN101541806A/zh active Pending
- 2007-09-19 AT AT07842799T patent/ATE532786T1/de active
- 2007-09-19 EP EP07842799A patent/EP2078022B1/en active Active
- 2007-09-19 ES ES07842799T patent/ES2374582T3/es active Active
- 2007-09-19 JP JP2009529369A patent/JP2010504351A/ja active Pending
-
2012
- 2012-01-24 CY CY20121100081T patent/CY1112270T1/el unknown
Also Published As
| Publication number | Publication date |
|---|---|
| CY1112270T1 (el) | 2015-12-09 |
| US20080076753A1 (en) | 2008-03-27 |
| ATE532786T1 (de) | 2011-11-15 |
| ES2374582T3 (es) | 2012-02-20 |
| JP2010504351A (ja) | 2010-02-12 |
| SI2078022T1 (sl) | 2012-01-31 |
| EP2078022A1 (en) | 2009-07-15 |
| DK2078022T3 (da) | 2012-02-13 |
| CN101541806A (zh) | 2009-09-23 |
| US7825110B2 (en) | 2010-11-02 |
| EP2078022B1 (en) | 2011-11-09 |
| PT2078022E (pt) | 2012-01-11 |
| AU2007299818B2 (en) | 2012-08-02 |
| WO2008036755A1 (en) | 2008-03-27 |
| AU2007299818A1 (en) | 2008-03-27 |
| CA2665849A1 (en) | 2008-03-27 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| SI2078022T1 (sl) | Spiro benzazepini, uporabljeni kot antagonisti vazopresina | |
| MY128065A (en) | Tricyclic benzodiazepines as vasopressin receptor antagonists | |
| MA33358B1 (fr) | Arylpyridine en tant qu'inhibiteurs de l'aldostérone synthase | |
| CR20140316A (es) | Derivados de indol como antagonistas receptores de s1p1 (divisional 10922) | |
| MY157525A (en) | Inhibitors of the renal outer medullary potassium channel | |
| MY146087A (en) | Tricyclic compound, compositions, and methods | |
| WO2009089537A3 (en) | Anti-cancer compounds | |
| MX2010006911A (es) | Antagonistas del receptor mineralcorticoide no esteroidal derivado de 6h-dibenzo [b,e] oxepina. | |
| TWI316057B (en) | Nonpeptide substituted spirobenzoazepines as vasopressin antagonists | |
| TW200515911A (en) | Substituted spirobenzazepines | |
| MX352548B (es) | Compuestos disustituidos de tetrahidrofuranilo como antagonistas de receptor de bradiquinina b1. | |
| DK1214323T3 (da) | Indoloazepiner som vasopressinreceptorantagonister | |
| YU32702A (sh) | Nepeptidni supstituisani benzotiazepini kao antagonisti vazopresina | |
| MA34462B1 (fr) | Composes de thiophene 2,3,5- trisubstitues et leurs utilisations | |
| PE20071234A1 (es) | Composiciones a base de bh4 para el tratamiento de la enfermedad vascular | |
| JP2012526773A5 (2) | ||
| DOP2009000047A (es) | Tiazol pirazolopirimidinas como antagonistas del receptor crf1 | |
| TN2013000050A1 (en) | Disubstituted tetrahydrofuranyl compounds as antagonists of the bradykinin b1 receptor |